Key Takeaways
- Margin recovery underway, revenue lags: Gross margins improved QoQ on better realizations and a US subsidiary contribution, but revenue stayed soft as tariff and GST uncertainty continued to suppress customer procurement.
- Dahej is live but barely contributing: The new facility commissioned cooling agents and clove derivatives in December but operated only ~20 days in the quarter, so its P&L impact was minimal and Krystal expenses are a current drag on EBITDA.
- The US tariff overhang is structural, not just cyclical: 60% of FY25 exports went to the US under tariffs; customers are now exhausting inventory, and the mitigation strategy (US-plus-one) faces a long, customer-driven due diligence process.
- FY28 targets reaffirmed despite near-term fog: Management held its INR1,050–1,100 cr revenue and 16–18% EBITDA margin targets for FY28, anchoring the story on Dahej ramp and Krystal breakeven in FY27.
- What to watch next quarter: Whether cooling-agent follow-up audits convert to orders, the pace of Dahej utilization ramp now that operations are continuous, and any concrete progress on US-plus-one facility approvals.
Dahej & Krystal: The Investment Cycle
- Dahej commissioning: Cooling agents (WS23, WS03) and clove/eugenol verticals were commissioned on 11 December 2025, with first-stage audits for FSSC 22000, GHP, HACCP and ISO certifications successfully completed.
- Limited Q3 contribution: Operations were restricted to approximately 20 days during the quarter, so revenue contribution was negligible while Krystal expenses continued to flow through, keeping EBITDA margins near 9%.
- Ramp-up timeline: Management expects more meaningful contribution from Q4 FY26 onward, with all products online by Q1 FY27 and utilization reaching 50–60% by FY27 end.
- Peak revenue potential: At current expansion, Dahej can deliver INR750–800 cr revenue in 2–3 years (sometime in FY29), assuming roughly 3x asset turn.
- Krystal breakeven: Expected to reach cash breakeven in FY27 at roughly 45% capacity utilization, with phenol derivatives, citral derivatives, and clove/eugenol requiring less inventory build than the initial ramp.
- Phenol derivatives progress: Catalyst preparation underway, expected completion by end of Q4 FY26; trial production of Anisole, MEHQ and Guaiacol planned for Q1 FY27, with 4-MAP and BHA to follow in a phased manner.
- Anisole technology: A clean vapor-phase-based process is ready, with the intent to manufacture Anisole in-house for cost-competitive advantages in downstream products (MEHQ, Guaiacol, BHA, 4-MAP, Anethole).
- Krystal approvals: The plant is currently under approvals by a handful of global majors who are consumers of phenol derivative products.
Yash Parekh: "The Dahej facility has been designed as a flexible multipurpose manufacturing platform, enabling rapid product transitions, faster commercialization cycles, and improved asset utilization across multiple chemistries."
Demand & Revenue Headwinds
- Tariff-driven export slowdown: A large portion of FY25 exports (60%) went to the US under tariffs; customers accepted product with tariffs but are now exhausting inventory, causing current pain in export demand.
- GST disruption in domestic market: The GST revision affected offtake primarily with unorganized and fragmented smaller suppliers and customers where price is the only consideration, and this issue is expected to persist.
- Green shoots in GST recovery: Clarity has emerged on the two-rate structure for menthol; companies have reworked formulations and adjusted blend requirements, and demand has started to come back from buyers who now understand the new normal, though the price-sensitive segment has not improved.
- Near-term uncertainty: Management expects near-term uncertainty to gradually ease, supporting improved business momentum, but declined to quantify the pace or commit to maintaining last year's numbers.
- Customer stickiness as a buffer: A large portion of business is with sticky customers; the top five have not changed in the last decade because once ingredients are approved in compositions, it is very difficult for customers to onboard someone else, though numbers within the top five may change year-on-year.
Suraj Shah: "The clarity has emerged, people have understood that to be the new normal, and they've adjusted their blend requirements. So we see like green shoots in demand coming from there."
Cooling Agents: The Next Growth Leg
- Customer engagement progressing: Large customers have reached out, and the first stage of multiple-stage audits has been successfully completed, with follow-up audits scheduled for completion by March and April.
- Production validation required: Customers want to see 3–5 production batches before the follow-up audit, a standard step in the qualification process for institutional buyers.
- Revenue recognition risk: Even if orders come in February–March, COP index accounting means shipments may not reach US seaports by March 31, so revenue may not be recognized in FY26, though inquiry and order flows are sequentially much higher than Q2 and Q3.
- Tariff exemption: Cooling agents are exempt from US tariffs under Annex II, insulating this vertical from the trade friction affecting other products.
US Tariff Mitigation: The US-Plus-One Strategy
- Strategy in motion: The company is actively pursuing US-plus-one strategies, where ingredients go into flavors and fragrances requiring significant due diligence.
- Customer-driven approval bottleneck: End customers (large institutional buyers) need to approve third-party facilities that would be taken on lease, rented, or contracted, and the process involves sending intermediates, manufacturing in the respective country, and meeting compliance and valuation norms.
- Long lead time: The due diligence process is inherently lengthy, and management acknowledged it as a constraint on how quickly the strategy can offset current tariff headwinds.
- GEM LLC dynamics: The US subsidiary saw renewed customer ordering as inventory exhausted, albeit at a slower pace, contributing to the QoQ gross margin improvement.
Yash Parekh: "There is significant amount of due diligence that is required on any US plus one strategy where the value addition criteria need to be met, as well as the production facilities need to be of a certain standard."
Financial Trajectory & Capital Allocation
- FY28 targets reaffirmed: Revenue of INR1,050–1,100 cr and EBITDA margins of 16–18% by FY28, with management continuing to believe these are achievable despite current headwinds.
- FY28 revenue split: Approximately INR650–700 cr from Krystal and INR400 cr from GEM, with the caveat that if clove is moved from GEM to Krystal, Krystal's share could be higher.
- Krystal US exposure is limited: Cooling agents and eugenol are exempt from US tariffs; citral derivatives are largely an import-substitution play; phenol derivatives are a mix of domestic and export, non-US.
- GEM refill needed: Current run-rate has been affected by tariffs for two quarters, and the product vertical is being gradually moved and will need to be refilled.
- Working capital outlook: Initially, Krystal will load up more inventory for ramp-up, though phenol derivatives, citral derivatives, and clove/eugenol will not require carrying as much inventory; management declined to give a 3-year working capital guide, asking to observe for a few more quarters.
- Quarterly margin phasing declined: When asked how margin improvement would phase out from Q1 FY27, management said it was tough to quantify quarterly, sticking to the FY28 target.
Suraj Shah: "I think the goal is to have all products come in, come online by like Q1 of next year. And then we observe our execution and we expect like 50%-60% by next year, by next year end."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | INR1,050–1,100 cr | FY28 |
| EBITDA margin target | 16–18% | FY28 |
| Krystal cash breakeven | At ~45% capacity utilization | FY27 |
| All products online at Dahej | Full product suite operational | Q1 FY27 |
| Dahej utilization | 50–60% | FY27 end |
| Dahej peak revenue | INR750–800 cr | FY29 (2–3 years) |
| Phenol derivatives trial production | Anisole, MEHQ, Guaiacol | Q1 FY27 |
| Cooling agent follow-up audits | Completion with large customers | March–April 2026 |
| Catalyst preparation for phenol derivatives | Completion | End of Q4 FY26 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated revenue | ₹78.9 cr |
| Standalone revenue | ₹83.9 cr |
| Consolidated gross margin | 23%, improved from 14% |
| Standalone gross margin | 18.4% |
| Consolidated EBITDA margin | 8.9%, improved from 3% |
| Standalone EBITDA margin | 9.1% |
| Consolidated net loss | ₹5 cr |
| Standalone net profit | ₹4.2 cr, PAT margin 5% |
| 9M FY26 consolidated revenue | ₹256.1 cr |
| 9M FY26 consolidated EBITDA margin | 9.7% |
| 9M FY26 consolidated net profit | ₹0.4 cr, PAT margin 0.2% |
| FY28 revenue target | ₹1,050 cr to ₹1,100 cr |
| FY28 EBITDA margin target | 16% to 18% |
| Dahej facility capex incurred | ~₹250 cr of ~₹270 cr total, largely capitalized |
| Dahej commercial production start | 11 December 2025, operations restricted to ~20 days in Q3 |
| Dahej peak revenue potential | ₹750 cr to ₹800 cr by FY29, based on 3x asset turn on current capacity |
| Dahej capacity utilization expectation | 45%–50% by end of FY27, cash breakeven at ~45% utilization |
| Total capacity post-Dahej | ~16,000 MTPA, effective 3x expansion |
| FY25 US export share | ~60% of total exports |